Gastric Cancer Treatments and Survival Trends in the United States
Autor: | Chan Shen, June S. Peng, Kelly A. Stahl, Matthew E.B. Dixon, Niraj J. Gusani, Madeline B. Torres, Elizabeth J. Olecki |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
medicine.medical_specialty
Multivariate analysis Guideline Concordant Care Disease Adenocarcinoma Article Cohort Studies multimodal therapy Stomach Neoplasms Internal medicine Humans Medicine guideline concordant care cancer survival RC254-282 business.industry gastric cancer treatment trends digestive oral and skin physiology Cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens Multimodal therapy Guideline medicine.disease digestive system diseases United States Chemotherapy Adjuvant National Cancer Database Cohort Guideline Adherence Stage iv business |
Zdroj: | Current Oncology, Vol 28, Iss 17, Pp 138-151 (2021) Current Oncology Volume 28 Issue 1 Pages 17-151 |
ISSN: | 1198-0052 1718-7729 |
Popis: | Gastric cancer is the third most common cause of cancer deaths worldwide. Despite evidence-based recommendation for treatment, the current treatment patterns for all stages of gastric cancer remain largely unexplored. This study investigates trends in the treatments and survival of gastric cancer. The National Cancer Database was used to identify gastric adenocarcinoma patients from 2004&ndash 2016. Chi-square tests were used to examine subgroup differences between disease stages: Stage I, II/III and IV. Multivariate analyses identified factors associated with the receipt of guideline concordant care. The Kaplan&ndash Meier method was used to assess three-year overall survival. The final cohort included 108,150 patients: 23,584 Stage I, 40,216 Stage II/III, and 44,350 Stage IV. Stage specific guideline concordant care was received in only 73% of patients with Stage I disease and 51% of patients with Stage II/III disease. Patients who received guideline consistent care had significantly improved survival compared to those who did not. Overall, we found only moderate improvement in guideline adherence and three-year overall survival during the 13-year study time period. This study showed underutilization of stage specific guideline concordant care for stage I and II/III disease. |
Databáze: | OpenAIRE |
Externí odkaz: |